Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
Open Access
- 17 November 2020
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2), e000960
- https://doi.org/10.1136/jitc-2020-000960
Abstract
Background To date, no systemic therapy, including immunotherapy, exists to improve clinical outcomes in metastatic uveal melanoma (UM) patients. To understand the role of immune infiltrates in the genesis, metastasis, and response to treatment for UM, we systematically characterized immune profiles of UM primary and metastatic tumors, as well as samples from UM patients treated with immunotherapies. Methods Relevant immune markers (CD3, CD8, FoxP3, CD68, PD-1, and PD-L1) were analyzed by immunohistochemistry on 27 primary and 31 metastatic tumors from 47 patients with UM. Immune gene expression profiling was conducted by NanoString analysis on pre-treatment and post-treatment tumors from patients (n=6) receiving immune checkpoint blockade or 4-1BB and OX40 dual costimulation. The immune signature of UM tumors responding to immunotherapy was further characterized by Ingenuity Pathways Analysis and validated in The Cancer Genome Atlas data set. Results Both primary and metastatic UM tumors showed detectable infiltrating lymphocytes. Compared with primary tumors, treatment-naïve metastatic UM showed significantly higher levels of CD3+, CD8+, FoxP3+ T cells, and CD68+ macrophages. Notably, levels of PD-1+ infiltrates and PD-L1+ tumor cells were low to absent in primary and metastatic UM tumors. No metastatic organ-specific differences were seen in immune infiltrates. Our NanoString analysis revealed significant differences in a set of immune markers between responders and non-responders. A group of genes relevant to the interferon-γ signature was differentially up-expressed in the pre-treatment tumors of responders. Among these genes, suppressor of cytokine signaling 1 was identified as a marker potentially contributing to the response to immunotherapy. A panel of genes that encoded pro-inflammatory cytokines and molecules were expressed significantly higher in pre-treatment tumors of non-responders compared with responders. Conclusion Our study provides critical insight into immune profiles of UM primary and metastatic tumors, which suggests a baseline tumor immune signature predictive of response and resistance to immunotherapy in UM.Funding Information
- National Cancer Institute (1R21CA208609-01, P30CA016672)
- University of Texas MD Anderson Cancer Center, Institutional Research Grant Award (#40080)
This publication has 48 references indexed in Scilit:
- The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian CancerPLOS ONE, 2013
- SOCS, inflammation, and cancerJAK-STAT, 2013
- Uveal Melanoma: The Inflammatory MicroenvironmentJournal of Innate Immunity, 2012
- Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism?Frontiers in Immunology, 2012
- Functional significance of B7-H1 expressed by human uveal melanoma cellsMolecular Medicine Reports, 2010
- Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cellsBMC Cancer, 2010
- Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic FactorsPLOS ONE, 2009
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature, 2008
- SOCS regulation of the JAK/STAT signalling pathwaySeminars in Cell & Developmental Biology, 2008
- Natural regulatory T cells: mechanisms of suppressionTrends in Molecular Medicine, 2007